New Shingles Vaccine: What You Need to Know New Shingles Vaccine: What You Need to Know

The shingles vaccine Shingrix was approved in 2017. Doctors say they are learning more about how it works, its safety risks, and how it compares to Zostavax.WebMD Health News
Source: Medscape Infectious Diseases Headlines - Category: Infectious Diseases Tags: Family Medicine/Primary Care News Source Type: news

Related Links:

Older adults who receive the Shingrix shingles vaccines are more than twice as likely to develop Guillain-Barr é syndrome compared with those given the older Zostavax product, a JAMA Internal Medicine study found.
Source: Health News - UPI.com - Category: Consumer Health News Source Type: news
CONCLUSIONS: More than half of the sub-sample reported not knowing about shingles vaccine, therefore, opportunities to increase awareness should be prioritized. Since provider recommendation and flu vaccination receipt had the greatest odds of increasing shingles vaccination, standard practice should include adding shingles to flu vaccine recommendations for age-eligible patients.PMID:34625290 | DOI:10.1016/j.vaccine.2021.09.032
Source: Vaccine - Category: Allergy & Immunology Authors: Source Type: research
(Reuters Health)—Adults 50 years and older who take tumor necrosis factor inhibitors (TNFi’s) for a range of inflammatory disorders can receive effective protection from shingles with a live varicella zoster vaccine, a clinical trial suggests.1 Researchers randomized 617 participants receiving TNFi’s in a 1:1 ratio to receive either the Zostavax live varicella zoster vaccine or... [Read More]
Source: The Rheumatologist - Category: Rheumatology Authors: Tags: Biologics & Biosimilars Drug Updates live vaccine varicella zoster vaccine varicella zoster virus Source Type: research
Background. Immunization of varicella-zoster virus (VZV)-seronegative solid organ transplant (SOT) patients using the live-attenuated varicella vaccine is generally contraindicated, leaving no widely applicable immunization option. The recombinant subunit herpes zoster vaccine (RZV) is indicated for VZV-seropositive persons to prevent shingles but could potentially also protect VZV-seronegative persons against varicella. We performed a safety and immunogenicity evaluation of RZV in VZV-seronegative SOT recipients as an option for protection. Methods. VZV-seronegative adult SOT patients with no history of varicel...
Source: Transplantation - Category: Transplant Surgery Tags: Original Clinical Science—General Source Type: research
NEW RESEARCH has found a vaccine containing live shingles, or varicella-zoster, is a safe and effective treatment for people living with inflammatory disorders, who are at a higher risk of developing shingles.
Source: Daily Express - Health - Category: Consumer Health News Source Type: news
CONCLUSION: This trial informs safety concerns related to use of live virus vaccines in patients receiving biologics.PRIMARY FUNDING SOURCE: The National Institute of Arthritis and Musculoskeletal and Skin Diseases and the American College of Rheumatology.PMID:34570596 | DOI:10.7326/M20-6928
Source: Annals of Internal Medicine - Category: Internal Medicine Authors: Source Type: research
Condition:   Herpes Zoster Interventions:   Biological: HZ/su;   Combination Product: Flu D-QIV;   Biological: mRNA-1273 Sponsor:   GlaxoSmithKline Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Health | Infectious Diseases | Learning | Primary Care | Shingles | Shingles (Herpes Zoster) Vaccine | Universities & Medical Training | Vaccines | Varicella-Zoster Virus Vaccine